
Following Luxturna and slate of eye disease approvals, Roche adds another ophthalmology partner for AAV gene therapies
Roche’s ophthalmology ambitions have grown steadily in recent years with two eye disease approvals in the past year and the acquisition of Spark and its Luxturna gene therapy in 2019, and the Big Pharma is doubling down in the space with another gene therapy tie-up.
Instead of Philadelphia, Roche has headed to Pittsburgh for this deal, linking arms with a University of Pittsburgh Medical Center spinout developing new AAV gene therapy vectors that the biotech’s CEO hopes will address limitations of existing treatments, including Luxturna. The deal also adds to Roche’s deep ophthalmology pipeline, which includes late-stage work attempting to secure more indications for recently approved Susvimo and Vabysmo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.